Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Open-Label Single-Arm Study of VAL-1221 in Lafora Disease
2023-000185-34Phase 2Terminated
- Sponsor
- Azienda USL di Bologna
- Start
- Feb 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of clervonafusp alfa in Lafora disease, sponsored by Azienda USL di Bologna. Primary endpoint: Safety profile of VAL-1221. Started Feb 2023; status: terminated.
02
Drugs
clervonafusp alfa
03
Conditions
Lafora disease
Beyond the preview
Go deeper on 2023-000185-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-000185-34.